Capravirine
Capravirine[edit | edit source]
Capravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was investigated for the treatment of HIV/AIDS. It belongs to a class of antiretroviral drugs that target the reverse transcriptase enzyme, which is crucial for the replication of the HIV virus.
Mechanism of Action[edit | edit source]
Capravirine works by binding to the reverse transcriptase enzyme of the HIV virus. This binding inhibits the enzyme's activity, preventing the conversion of viral RNA into DNA, a critical step in the viral replication cycle. By blocking this process, capravirine helps to reduce the viral load in patients infected with HIV.
Development and Clinical Trials[edit | edit source]
Capravirine was developed as part of efforts to expand the arsenal of drugs available to treat HIV/AIDS, particularly in cases where the virus has developed resistance to other NNRTIs. During clinical trials, capravirine showed promise in reducing viral loads in patients. However, its development was eventually discontinued due to concerns about its efficacy and safety profile compared to other available treatments.
Pharmacokinetics[edit | edit source]
Capravirine is administered orally and undergoes extensive metabolism in the liver. It is primarily metabolized by the cytochrome P450 enzyme system, which can lead to significant drug-drug interactions. The pharmacokinetic profile of capravirine necessitated careful consideration of dosing regimens to optimize its therapeutic effects while minimizing adverse reactions.
Adverse Effects[edit | edit source]
Like many antiretroviral drugs, capravirine was associated with a range of potential side effects. Common adverse effects included gastrointestinal disturbances, such as nausea and diarrhea, as well as skin rashes. More serious side effects, although less common, included hepatotoxicity and hypersensitivity reactions.
Discontinuation[edit | edit source]
The development of capravirine was halted after phase II clinical trials. The decision was based on the emergence of more effective NNRTIs with better safety profiles and fewer drug-drug interactions. As a result, capravirine did not proceed to phase III trials and was never approved for clinical use.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
